Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by NAOTO T UENO and VICENTE VALERO.
NAOTO T UENO
Connection Strength
5.272
VICENTE VALERO
  1. Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. Cancer Res Commun. 2024 Oct 01; 4(10):2823-2834.
    View in: PubMed
    Score: 0.248
  2. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness". Cell Rep Med. 2024 Jun 18; 5(6):101595.
    View in: PubMed
    Score: 0.242
  3. Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy. Clin Cancer Res. 2024 Jun 03; 30(11):2424-2432.
    View in: PubMed
    Score: 0.242
  4. Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review. PLoS One. 2021; 16(4):e0250057.
    View in: PubMed
    Score: 0.195
  5. Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. Cancers (Basel). 2020 Oct 24; 12(11).
    View in: PubMed
    Score: 0.188
  6. Update on systemic treatment for newly diagnosed inflammatory breast cancer. J Adv Res. 2021 03; 29:1-12.
    View in: PubMed
    Score: 0.187
  7. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream? in patients with breast cancer treated with primary systemic therapy. PLoS One. 2020; 15(3):e0229903.
    View in: PubMed
    Score: 0.181
  8. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. Oncologist. 2020 06; 25(6):e909-e919.
    View in: PubMed
    Score: 0.179
  9. A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. Br J Cancer. 2019 06; 120(12):1105-1112.
    View in: PubMed
    Score: 0.171
  10. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Invest New Drugs. 2019 04; 37(2):345-351.
    View in: PubMed
    Score: 0.166
  11. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. 2018 09 01; 4(9):1207-1213.
    View in: PubMed
    Score: 0.162
  12. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer. 2018 12; 18(6):e1283-e1288.
    View in: PubMed
    Score: 0.161
  13. International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer. 2018; 9(8):1437-1447.
    View in: PubMed
    Score: 0.158
  14. Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system. Lancet Oncol. 2017 04; 18(4):e228-e232.
    View in: PubMed
    Score: 0.147
  15. Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Res Treat. 2017 Jun; 163(2):263-272.
    View in: PubMed
    Score: 0.146
  16. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis. JAMA Oncol. 2015 Dec; 1(9):1311-8.
    View in: PubMed
    Score: 0.134
  17. Erratum to: Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat. 2015 Jul; 152(2):417.
    View in: PubMed
    Score: 0.130
  18. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat. 2015 Jul; 152(2):407-16.
    View in: PubMed
    Score: 0.130
  19. Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. J Cancer. 2015; 6(4):310-8.
    View in: PubMed
    Score: 0.126
  20. Clinical characteristics and outcome of bone-only metastasis in inflammatory and noninflammatory breast cancers. Clin Breast Cancer. 2015 Feb; 15(1):37-42.
    View in: PubMed
    Score: 0.123
  21. Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. Springerplus. 2013; 2:409.
    View in: PubMed
    Score: 0.115
  22. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013 Oct 01; 19(19):5533-40.
    View in: PubMed
    Score: 0.114
  23. Metastasis in the breast mimicking inflammatory breast cancer. J Clin Oncol. 2012 Aug 01; 30(22):e202-6.
    View in: PubMed
    Score: 0.106
  24. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat. 2011 Feb; 125(3):785-95.
    View in: PubMed
    Score: 0.095
  25. Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients. Br J Cancer. 2010 Oct 26; 103(9):1331-4.
    View in: PubMed
    Score: 0.094
  26. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer. 2007 Feb; 7(6):471-9.
    View in: PubMed
    Score: 0.073
  27. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol. 2023; 15:17588359231189422.
    View in: PubMed
    Score: 0.057
  28. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel). 2023 Jun 21; 15(13).
    View in: PubMed
    Score: 0.057
  29. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs. 2023 Jun; 41(3):391-401.
    View in: PubMed
    Score: 0.056
  30. Phenotypic Plasticity in Circulating Tumor Cells Is Associated with Poor Response to Therapy in Metastatic Breast Cancer Patients. Cancers (Basel). 2023 Mar 06; 15(5).
    View in: PubMed
    Score: 0.056
  31. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clin Cancer Res. 2022 07 01; 28(13):2878-2889.
    View in: PubMed
    Score: 0.053
  32. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel). 2022 Mar 04; 14(5).
    View in: PubMed
    Score: 0.052
  33. Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. Ann Surg Oncol. 2021 Dec; 28(13):8610-8621.
    View in: PubMed
    Score: 0.049
  34. The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. Ann Surg Oncol. 2021 Aug; 28(8):4265-4274.
    View in: PubMed
    Score: 0.048
  35. Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer. Breast Cancer Res Treat. 2019 Aug; 176(3):545-556.
    View in: PubMed
    Score: 0.043
  36. Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center. PLoS One. 2018; 13(9):e0204372.
    View in: PubMed
    Score: 0.041
  37. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. 2018 06 01; 124(11):2299-2305.
    View in: PubMed
    Score: 0.039
  38. Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. J Cancer. 2017; 8(11):2004-2009.
    View in: PubMed
    Score: 0.037
  39. Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget. 2017 May 30; 8(22):35656-35668.
    View in: PubMed
    Score: 0.037
  40. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. Cancer. 2017 Jul 01; 123(13):2422-2431.
    View in: PubMed
    Score: 0.036
  41. Disparities in the Use of Postmastectomy Radiation Therapy for Inflammatory Breast?Cancer. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1218-25.
    View in: PubMed
    Score: 0.034
  42. Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes Control. 2016 Mar; 27(3):359-66.
    View in: PubMed
    Score: 0.034
  43. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. Oncologist. 2016 Jan; 21(1):21-7.
    View in: PubMed
    Score: 0.034
  44. Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. J Natl Cancer Inst. 2015 Nov; 107(11).
    View in: PubMed
    Score: 0.033
  45. Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. Cancer. 2015 Dec 15; 121(24):4324-32.
    View in: PubMed
    Score: 0.033
  46. Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. Am J Clin Oncol. 2015 Jun; 38(3):242-7.
    View in: PubMed
    Score: 0.032
  47. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Res. 2015 Jan 09; 17:2.
    View in: PubMed
    Score: 0.032
  48. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS One. 2014; 9(1):e83113.
    View in: PubMed
    Score: 0.029
  49. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther. 2012 Nov; 11(11):2526-34.
    View in: PubMed
    Score: 0.027
  50. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer. 2012 Aug; 12(4):264-9.
    View in: PubMed
    Score: 0.026
  51. Inflammatory breast cancer: what we know and what we need to learn. Oncologist. 2012; 17(7):891-9.
    View in: PubMed
    Score: 0.026
  52. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol. 2012 Mar 01; 30(7):729-34.
    View in: PubMed
    Score: 0.026
  53. Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):1381-6.
    View in: PubMed
    Score: 0.026
  54. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist. 2011; 16(12):1675-83.
    View in: PubMed
    Score: 0.025
  55. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol. 2012 May; 23(5):1144-1150.
    View in: PubMed
    Score: 0.025
  56. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer. 2011 Dec 15; 117(24):5476-84.
    View in: PubMed
    Score: 0.025
  57. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 2011 Jun 15; 13(3):R67.
    View in: PubMed
    Score: 0.025
  58. Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. Int J Cancer. 2011 Jul 15; 129(2):417-23.
    View in: PubMed
    Score: 0.024
  59. Incidence of and survival following brain metastases among women with inflammatory breast cancer. Ann Oncol. 2010 Dec; 21(12):2348-2355.
    View in: PubMed
    Score: 0.023
  60. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol. 2010 Jan; 21(1):33-9.
    View in: PubMed
    Score: 0.022
  61. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001 Oct 01; 92(7):1775-82.
    View in: PubMed
    Score: 0.013
  62. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J. 2001 Sep-Oct; 7(5):413-20.
    View in: PubMed
    Score: 0.012
  63. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol. 2001 Jul 15; 19(14):3422-33.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.